Trial Profile

A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allo 715 (Primary) ; ALLO 647; Cyclophosphamide; Fludarabine; Nirogacestat
Indications Multiple myeloma
Focus Adverse reactions; First in man; Proof of concept; Registrational
Acronyms UNIVERSAL
Sponsors Allogene Therapeutics

09 Aug 2023 Planned End Date changed from 1 Dec 2027 to 1 Sep 2027.
09 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Sep 2027.
09 Aug 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com